Abstract
Indications of endocarditis prophylaxis have changed in the past years, because of the absence of any evidence that justified its use. The last guidelines only recommend prophylaxis in patients with underlying cardiac conditions with the higher risk of adverse outcomes, including patients with a previous history of infective endocarditis, patients with prosthetic heart valve or prosthetic material used for valve repair, patients with a valvulopathy after cardiac transplantation, and patients with an specific congenital heart disease. The list of procedures in which prophylaxis is necessary has been limited too. Nowadays it is recommended in patients who undergo any dental procedure that involves the gingival tissues or periapical region of a tooth and for those invasive procedures of the oral cavity or an invasive procedure of the respiratory tract that involves incision or biopsy of the respiratory mucosa. In this revision we try to expose the recent tendencies recommended by the international guidelines.
Keywords: Infective endocarditis, prophylaxis
Related Journals
Related eBooks
Related Articles
-
Linezolid in Children: Recent Patents and Advances
Recent Patents on Anti-Infective Drug Discovery Drug-Induced Thromboembolic Events in Patients with Malignancy
Cardiovascular & Hematological Disorders-Drug Targets Vaccine Therapy for P. acnes-Associated Diseases
Infectious Disorders - Drug Targets Nonbacterial Thrombotic Endocarditis (Marantic Endocarditis) in Cancer Patients
Cardiovascular & Hematological Disorders-Drug Targets Susceptibility of Intracellular Coxiella burnetii to Antimicrobial Peptides in Mouse Fibroblast Cells
Protein & Peptide Letters Non-Microbicidal Control of Bacterial Biofilms with Small Molecules
Anti-Infective Agents Antibiotic Susceptibility and Treatment of Brucellosis
Recent Patents on Anti-Infective Drug Discovery Diagnostic and Therapeutic Nanoparticles in Cardiovascular Diseases
Current Pharmaceutical Design Riboswitches as Potential Targets for the Development of Anti-Biofilm Drugs
Current Topics in Medicinal Chemistry Antibiotic Treatment in Native Valve Infective Endocarditis
Infectious Disorders - Drug Targets Immunopathology of Brucella Infection
Recent Patents on Anti-Infective Drug Discovery Small Molecule Inhibitors Limit Endothelial Cell Invasion by Staphylococcus aureus
Current Pharmaceutical Biotechnology Oral Inflammation and Bacteremia: Implications for Chronic and Acute Systemic Diseases Involving Major Organs
Cardiovascular & Hematological Disorders-Drug Targets Dealing with the Substance Abuse Epidemic and Infective Endocarditis:Clinical, Immunologic and Pathogenetic Aspects
Current Vascular Pharmacology New Perspectives of Infections in Cardiovascular Disease
Current Cardiology Reviews Structure and Function of the Type III Secretion System of Pseudomonas aeruginosa
Current Protein & Peptide Science Biosynthesis and Genetic Engineering of Lipopeptide Antibiotics Related to Daptomycin
Current Topics in Medicinal Chemistry Infective Endocarditis Complicating Hypertrophic Obstructive Cardiomyopathy: Is Antibiotic Prophylaxis Really Unnecessary?
Current Cardiology Reviews Prevention of Bacterial Endocarditis
Cardiovascular & Hematological Disorders-Drug Targets Complications of Infective Endocarditis
Cardiovascular & Hematological Disorders-Drug Targets